Abstract
Diagnosis and treatment of interdigitating dendritic cell sarcoma (IDCS), a rare tumor of histiocytic origin, remain a challenge for both pathologists and hematologists/oncologists. Due to its rarity, there is no well-defined therapeutic regimen for this neoplasm. We report a case of IDCS with aberrant expression of epidermal growth factor receptor (EGFR) which was not detected in the normal follicular dendritic cells and interdigitating dendritic cells with immunohistochemistry. Molecular studies of the tumor showed no mutation in either the EGFR gene or KRAS gene. Our findings suggest that EGFR could be a novel diagnostic biomarker and therapeutic target for IDCS.
Keywords
Epidermal growth factor receptor (EGFR), interdigitating dendritic cell sarcoma (IDCS), KRAS
How to Cite
Zhao, X. F. & Li, S., (2020) “Interdigitating Dendritic Cell Sarcoma with Aberrant EGFR Expression”, Hematopathology 5(1), 6-11.
189
Views
84
Downloads